1: The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies B.G. Murphy, M. Perron, E. Murakami, K. Bauer, Y. Park, C. Eckstrand, M. Liepnieks, N.C. Pedersen Vet Microbiol. 2018 Jun; 219: 226–233. Published online 2018 Apr 22. doi: 10.1016/j.vetmic.2018.04.026 PMCID: PMC7117434
2: Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease Valeria Avataneo, Amedeo de Nicolò, Jessica Cusato, Miriam Antonucci, Alessandra Manca, Alice Palermiti, Catriona Waitt, Stephen Walimbwa, Mohammed Lamorde, Giovanni di Perri, Antonio D’Avolio J Antimicrob Chemother. 2020 May 3 : dkaa152. Published online 2020 May 3. doi: 10.1093/jac/dkaa152 PMCID: PMC7197584
3: Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis Niels C Pedersen, Michel Perron, Michael Bannasch, Elizabeth Montgomery, Eisuke Murakami, Molly Liepnieks, Hongwei Liu J Feline Med Surg. 2019 Apr; 21(4): 271–281. Published online 2019 Feb 13. doi: 10.1177/1098612X19825701 PMCID: PMC6435921
4: Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses E. Susan Amirian, Julie K. Levy One Health. 2020 Jun; 9: 100128. Published online 2020 Mar 27. doi: 10.1016/j.onehlt.2020.100128 PMCID: PMC7118644
5: Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease Maria L. Agostini, Erica L. Andres, Amy C. Sims, Rachel L. Graham, Timothy P. Sheahan, Xiaotao Lu, Everett Clinton Smith, James Brett Case, Joy Y. Feng, Robert Jordan, Adrian S. Ray, Tomas Cihlar, Dustin Siegel, Richard L. Mackman, Michael O. Clarke, Ralph S. Baric, Mark R. Denison mBio. 2018 Mar-Apr; 9(2): e00221-18. Published online 2018 Mar 6. doi: 10.1128/mBio.00221-18 PMCID: PMC5844999
6: Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
Ashleigh Shannon, Nhung Thi Tuyet Le, Barbara Selisko, Cecilia Eydoux, Karine Alvarez, Jean-Claude Guillemot, Etienne Decroly, Olve Peersen, Francois Ferron, Bruno Canard Antiviral Res. 2020 Apr 10 : 104793. doi: 10.1016/j.antiviral.2020.104793 [Epub ahead of print] PMCID: PMC7151495
7: Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 Richard T. Eastman, Jacob S. Roth, Kyle R. Brimacombe, Anton Simeonov, Min Shen, Samarjit Patnaik, Matthew D. Hall ACS Cent Sci. 2020 May 4 : acscentsci.0c00489. Published online 2020 May 4. doi: 10.1021/acscentsci.0c00489 PMCID: PMC7202249
8: Artificial intelligence approach fighting COVID-19 with repurposing drugs Yi-Yu Ke, Tzu-Ting Peng, Teng-Kuang Yeh, Wen-Zheng Huang, Shao-En Chang, Szu-Huei Wu, Hui-Chen Hung, Tsu-An Hsu, Shiow-Ju Lee, Jeng-Shin Song, Wen-Hsing Lin, Tung-Jung Chiang, Jiunn-Horng Lin, Huey-Kang Sytwu, Chiung-Tong Chen Biomed J. 2020 May 15 doi: 10.1016/j.bj.2020.05.001 [Epub ahead of print] PMCID: PMC7227517